Pipeline

PIPELINE

Optimized and Genetically-Engineered TIL Therapies

Our optimized TIL therapies leverage our platform for TIL manufacturing, which has been designed to improve the scalability, logistics, and accessibility of TIL therapy. We are also developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform.

Optimized TIL
Candidate Indication Discovery IND-Enabling Phase 1 Phase 2/3 Upcoming Milestones
ITIL-168 Melanoma
Initiation of Phase 2* trial
ITIL-168 CSCC
Initiation of Phase 1 trial
ITIL-168 NSCLC
Initiation of Phase 1 trial
ITIL-168 HNSCC
Initiation of Phase 1 trial
ITIL-168 Cervical Cancer
Initiation of Phase 1 trial
CoStAR-TIL
Candidate Indication Discovery IND-Enabling Phase 1 Phase 2/3 Upcoming Milestones
ITIL-306 GYN, NSCLC, Other
IND filing
Undisclosed GI, Other
Candidate Selection

*Initiation of Phase 2 trial based on strength of clinical results from a compassionate use program and subject to acceptance of IND by FDA

CSCC: cutaneous squamous cell carcinoma; NSCLC: non-small cell lung cancer; HNSCC: head and neck squamous cell carcinoma; GYN: gynecological malignancies; GI: gastrointestinal malignancies